3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

Home-Grown Partnership Pays Dividends

 
• By Brian Yang
  
winners from China NRDL scheme
FIRST SUBCUTANEOUS IMMUNO-ONCOLOGY DRUG APPROVAL FROM CHINA'S 3D MED AND ALPHAMAB • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip